Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
33.92
-1.66 (-4.65%)
At close: Nov 14, 2025, 4:00 PM EST
34.00
+0.08 (0.22%)
After-hours: Nov 14, 2025, 4:10 PM EST
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $17.26M in the quarter ending June 30, 2025, with 217.71% growth. This brings the company's revenue in the last twelve months to $23.93M, up 264.86% year-over-year. In the year 2024, Sol-Gel Technologies had annual revenue of $11.54M with 642.47% growth.
Revenue (ttm)
$23.93M
Revenue Growth
+264.86%
P/S Ratio
3.96
Revenue / Employee
$703,853
Employees
34
Market Cap
94.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.54M | 9.98M | 642.47% |
| Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
| Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
| Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
| Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLGL News
- 3 months ago - Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 months ago - Sol-Gel Reports First Quarter 2025 Results - GlobeNewsWire
- 7 months ago - Sol-Gel Announces Reverse Share Split - GlobeNewsWire
- 7 months ago - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - GlobeNewsWire
- 7 months ago - Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis - GlobeNewsWire
- 1 year ago - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire